Overview

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of age and older. The results of this study will be utilized to perform power calculations for the Phase 3 pivotal trials.
Phase:
Phase 2
Details
Lead Sponsor:
Sol-Gel Technologies, Ltd.